[Radiofrequency ablation for hepatocellular carcinoma and colorectal liver metastases]

Gugerbauer J, Warmuth M
Record ID 32011001582
German
Authors' objectives:

Besides conventional surgical resection (SRS) radiofrequency ablation (RFA) represents a new, alternative treatment option for patients with hepatic malignancies, such as hepatocellular carcinoma (HCC) and colorectal liver metastases (CRLM). With RFA, tumor tissue is destroyed by applying heat (80-110°C) that is delivered by electrodes and leads to a necrosis and local ablation of the tumor. This systematic review aims at comparing the efficacy and safety of RFA and surgical resection for the treatment of both HCC and CRLM.

Authors' recommendations: In conclusion, for the treatment of hepatic malignancies (HCC and CRLM) it appears that SRS is superior to RFA in terms of selected efficacy outcomes (5-year-survival, recurrence). However, the advantage of RFA seems to be a lower intervention-associated mortality and morbidity in the treatment of HCC compared with SRS. Due to a lack of evidence, no conclusion can be drawn on the safety of RFA for CRLM.
Details
Project Status: Completed
Year Published: 2011
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Austria
MeSH Terms
  • Ablation Techniques
  • Liver Neoplasms
  • Neoplasm Metastasis
Contact
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: tarquin.mittermayr@aihta.at
Contact Email: office@aihta.at
Copyright: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.